# Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients

> **NCT02479399** · — · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 11412 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** ipragliflozin

## Key facts

- **NCT ID:** NCT02479399
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-17
- **Primary completion:** 2018-10-16
- **Final completion:** 2018-10-16
- **Target enrollment:** 11412 (ACTUAL)
- **Last updated:** 2024-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02479399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02479399, "Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02479399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*